Suppr超能文献

米托蒽醌作为一种有前途的光动力疗法乳腺癌的光敏剂。

Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer.

机构信息

Department of Medical Physics, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Photodiagnosis Photodyn Ther. 2012 Mar;9(1):46-51. doi: 10.1016/j.pdpdt.2011.08.004. Epub 2011 Oct 1.

Abstract

Photodynamic therapy has the potential to become an effective alternate to surgery for the treatment of cancer. In recent years, there has been a focus on identifying more effective and less toxic photosentisizers for use in photodynamic therapy. The purpose of this study was to assess the effectiveness of mitoxantrone, a chemotherapeutic agent, as a photosensitizer for photodynamic therapy in the MCF-7 human breast cancer cell line. Cytotoxicity was evaluated for different concentrations of mitoxantrone, and photosensitivity was assessed using a non-coherent light source. The percentage of the cell survival after 24 h was investigated using the MTT assay. Overall, the results showed that mitoxantrone is a remarkably efficient photosensitizer that could mediate MCF-7 cell death at a low concentration (5 μM) with modest exposure to light. It is surprising to find that a chemotherapeutic agent can be an effective photosensitizer for PDT in vitro.

摘要

光动力疗法有可能成为癌症治疗的一种有效替代手术的方法。近年来,人们一直致力于寻找更有效、毒性更低的光敏剂用于光动力疗法。本研究旨在评估米托蒽醌作为一种光敏剂在 MCF-7 人乳腺癌细胞系中的光动力疗法的效果。用不同浓度的米托蒽醌评估细胞毒性,并使用非相干光源评估光敏性。用 MTT 测定法研究了 24 小时后细胞存活率的百分比。总的来说,结果表明米托蒽醌是一种非常有效的光敏剂,在适度光照下,低浓度(5 μM)就可以介导 MCF-7 细胞死亡。令人惊讶的是,一种化疗药物可以成为体外 PDT 的有效光敏剂。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验